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Mycobacterium lentiﬂ  avum, a slow-growing nontuber-
culous mycobacterium, is a rare cause of human disease. It 
has been isolated from environmental samples worldwide. 
To assess the clinical signiﬁ  cance of M. lentiﬂ  avum isolates 
reported to the Queensland Tuberculosis Control Centre, 
Australia, during 2001–2008, we explored the genotypic 
similarity and geographic relationship between isolates from 
humans and potable water in the Brisbane metropolitan 
area. A total of 47 isolates from 36 patients were reported; 
4 patients had clinically signiﬁ  cant disease. M. lentiﬂ  avum 
was cultured from 13 of 206 drinking water sites. These 
sites overlapped geographically with home addresses of the 
patients who had clinically signiﬁ  cant disease. Automated 
repetitive sequence–based PCR genotyping showed a 
dominant environmental clone closely related to clinical 
strains. This ﬁ  nding suggests     potable water as a possible 
source of M. lentiﬂ  avum infection in humans.
M
ycobacterium lentiﬂ  avum organisms are nontuber-
culous mycobacteria (NTM) ﬁ  rst  identiﬁ  ed  in 
1996 (1). M. lentiﬂ  avum is slow growing at 22°C–37°C 
and has yellow pigmentation, negative tests for Tween 
80 hydrolysis, nicotinic acid, nitrate reductase and urease, 
distinct fatty and mycolic acid patterns, and unique 16S 
rRNA and 65-kDa heat-shock protein gene sequences. 
It shares phenotypic features with M. avium but is more 
closely related to M. simiae and M. genavense. Because of 
similarities to M.    avium complex (MAC), differentiation 
can be difﬁ  cult without molecular identiﬁ  cation, hence, 
misclassiﬁ  cation in the past is possible (2).
As with other NTM, M. lentiﬂ  avum has been isolated 
from soil and water samples around the world. However, 
links between environmental sources and human disease 
have not yet been demonstrated.
In Queensland, Australia (population 4.28 million), 
NTM disease is notiﬁ  able. A central reference laboratory 
performs speciation of all positive isolates. In 2008, ≈900 
isolates of NTM were reported.
Strain variation within mycobacterial species is well 
known. Although epidemiologic studies provide useful 
information, molecular strain typing can be invaluable, 
especially if a single clone can be linked to an outbreak 
source. Pulsed-ﬁ  eld gel electrophoresis (PFGE) has been 
considered the standard for mycobacterial strain typing 
but is time- and labor- intensive and requires expensive 
dedicated equipment. Also, DNA degradation can 
occur during electrophoresis, generating uninterpretable 
banding patterns (3). Repetitive sequence–based PCR 
(rep-PCR) has been used to differentiate mycobacterial 
strains associated with disease outbreaks in mesotherapy 
clinics (M. abscessus and M. chelonae) (4) and in patients 
after surgery (M. fortuitum) (5). An automated rep-PCR 
system (DiversiLab; bioMérieux, Melbourne, Victoria, 
Australia) showed high concordance with PFGE results (6) 
in identifying mycobacterial strain clusters and was faster 
than PFGE.
We had 2 goals for this study. First, we aimed to 
describe the clinical signiﬁ   cance and outcomes of M. 
lentiﬂ  avum infection in Queensland. Second, we intended 
to explore the genotypic and geographic relationship 
between patient isolates and potable water isolates in the 
Brisbane area.
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Methods
We reviewed the records of all patients from whom M. 
lentiﬂ  avum had been isolated during July 2001–November 
2008. Attending physicians were contacted to establish 
clinical signiﬁ   cance according to American Thoracic 
Society (ATS)/Infectious Diseases Society of America 
(IDSA) criteria (2) (Table 1). During 2007–2008, potable 
water was collected from 206 sites in Brisbane’s drinking 
water system.
Laboratory Identiﬁ  cation
Human samples were digested and decontaminated 
by using 4% NaOH, neutralized with phosphoric acid, 
and centrifuged to concentrate the acid-fast bacilli (AFB). 
Smears were prepared from the sediment and stained 
by the Ziehl-Neelsen (ZN) method. We injected cells 
into 1 Lowenstein-Jensen slope (± pyruvate) and 7-mL 
mycobacterial growth indicator tube, then incubated 
them at 35°C until growth was detected. ZN staining 
of colonies conﬁ   rmed AFB. Multiplex PCR (7) was 
performed to discriminate between M. tuberculosis, 
M. avium,  M. intracellulare,  M. abscessus, and other 
Mycobacterium spp. Other Mycobacterium spp. were 
further speciated by using Hain Life Sciences GenoType 
Mycobacterium AS (additional species) kit (2004–2007 
only; Hain Lifescience, Nehren, Germany) and/or 
16S rRNA sequencing in conjunction with phenotypic 
characteristics.
Water Sampling
Water was collected from routine sampling sites across 
Brisbane and processed according to described methods 
(8). Each 1,000-mL sample was transported at 4°C and 
processed within 24 hours. Half of each sample was 
decontaminated by using 0.005% cetylpiridinium chloride, 
and each 500-mL aliquot was ﬁ  ltered separately by using 
45-μm cellulose nitrate ﬁ  lters (Sartorius AG, Gottingen, 
Germany). The ﬁ  lters were rinsed and macerated in 3 mL 
sterile distilled water. Aliquots (0.1 mL) were transferred 
in triplicate to M7H11 plates, sealed in gas-permeable 
plastic bags, and incubated at 32°C. Aliquots (0.5 mL) 
were transferred to 2 mycobacterial growth indicator tubes, 
1 of which contained polymyxin, azlocillin, nalidixic acid, 
trimethoprim, and amphotericin B. ZN staining of colonies 
conﬁ  rmed AFB, and these colonies were subcultured on 
M7H11 plates. Multiplex PCR was performed (7) followed 
by 16S rRNA sequencing of mycobacterial isolates and 
compared by using Ribosomal Differentiation of Medical 
Microorganisms and GenBank databases (9,10).
Automated Rep-PCR Strain Typing
The similarity of 16 clinical and 7 water isolates was 
determined by using a rep-PCR method (DiversiLab). 
DNA was extracted from clinical and water isolates 
by using the Ultraclean Microbial DNA Isolation Kit 
(Mobio Laboratories, Carlsbad, CA, USA). PCR mixture 
was prepared by using AmpliTaq polymerase and PCR 
buffer (Applied Biosystems, Foster City, CA, USA) and 
Mycobacterium DiversiLab primer mix according to the 
manufacturer’s instructions. Rep-PCR products were 
separated and detected by using microﬂ   uidic chips of 
the DiversiLab system. Fingerprints were analyzed with 
DiversiLab software version 3.4.38 by using the Pearson 
correlation coefﬁ  cient and unweighted pair-group method 
with arithmetic means to compare isolates and determine 
clonal relationships.
Results
Clinical Isolates
Forty-seven isolates of M. lentiﬂ  avum were reported 
from 36 patients (Figure 1; Table  2). Full clinical information 
was available for 32 (89%) patients. Four patients (8 
isolates) had clinically signiﬁ  cant disease. Seven patients 
were taking treatment or were under surveillance for MAC 
(1 or 2 isolates each); no treatment changed in response to 
the new isolate, and thus these isolates were not considered 
clinically signiﬁ  cant. Twenty-one other patients (18 adults, 
3 children) had clinically nonsigniﬁ   cant isolates. Four 
patients had probable nonsigniﬁ  cant isolates, but sufﬁ  cient 
clinical information was lacking. No cases demonstrated 
positive AFB smears by ZN staining. Of the 32 patients 
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Table 1. American Thoracic Society/Infectious Diseases Society 
of America diagnostic criteria for NTM lung disease* 
Clinical criteria   
  Pulmonary symptoms AND 
  Nodular or cavitary opacities on chest radiograph OR 
  Multifocal bronchiectasis with multiple small nodules on  
  high-resolution computerized tomography AND 
  Appropriate exclusion of other diagnoses 
Microbiologic
  Positive culture results from at least 2 separate expectorated 
  sputum samples OR 
  Positive culture results from at least 1 bronchial wash or  
 lavage  OR 
  Biopsy† showing granulomatous inflammation or acid-fast  
 bacilli  and positive culture OR 
  Biopsy† showing granulomatous inflammation or acid-fast 
 bacilli  and one or more culture-positive sputum or bronchial  
 washings 
Comments 
x  Risk-benefit of therapy should be considered for each patient 
  before institution of therapy 
x  Expert consultation should be obtained when NTM are  
  recovered that are either infrequently encountered or that  
  usually represent environmental contamination 
x  Patients suspected of having NTM lung disease but who do  
  not meet the diagnostic criteria should be followed until the  
  diagnosis is firmly established or excluded 
*Adapted from (2). NTM, nontuberculous mycobacteria. 
†Transbronchial or other lung biopsy. M. lentiﬂ  avum in Drinking Water Supplies
with uncertain or nonsigniﬁ  cant disease, 26 had 1 positive 
specimen, 2 had 2 positive specimens from the same 
period, 3 had 2 positive specimens separated by 3 months, 
and 1 had 2 positive specimens separated by 11 months. 
Antimicrobial drug susceptibility tests were performed for 
2 isolates (cases 1 and 2 below). Both were sensitive to 
clarithromycin 4.0 μg/mL and resistant to isoniazid 0.4 μg/
mL, ethambutol 5.0 μg/mL, and streptomycin 1.0 μg/mL. 
The case 1 isolate was sensitive to oﬂ  oxacin 2.0 μg/mL; the 
case 2 isolate was resistant to rifampin 1.0 μg/mL.
Environmental Isolates
Mycobacteria were grown from 70% of water sites. 
The predominant isolates were M.  gordonae and M. 
kansasii. M. lentiﬂ  avum was isolated from 13 (6.3%) sites, 
2 of which were reservoirs, 1 a treatment plant, and the 
remainder points in the distribution system. Eleven sites 
shared the same groundwater source but were distributed 
among 10 different reservoir zones. For 12 patients living 
within 20 km of Brisbane central business district, the mean 
distance between their residential addresses and nearest 
positive water site was 3.49 km (range 0.9–9.8 km). The 
4 persons with clinically signiﬁ  cant illness lived a mean of 
2.7 km from a positive water site (Figure 2).
Case Descriptions for Signiﬁ  cant Isolates
The 4 patients whose disease met the ATS/IDSA 
criteria are described below. All specimens were ZN stain 
negative.
Case 1: Disseminated Infection
A 43-year-old woman who smoked had a background 
of intravenous drug use and HIV. In 1998, granulomatous 
hepatomegaly developed, thought to be a reaction from 
injecting methadone mixed with orange juice, and resolved 
after she ceased this activity. A tunneled intravenous 
access device was placed in February 2006. In April 
2007, she sought care for hepatosplenomegaly and mild 
pancytopenia. Liver and gastric lymph node biopsies 
showed granulomata. Two bone marrow biopsy samples 
taken 6 weeks apart showed initially scant, but then 
more marked, granulomata. All specimens were culture 
negative for AFB. A working diagnosis of sarcoidosis was 
made, and prednisone with highly active antiretroviral 
therapy (tenofovir, emtricitabine, and efavirenz) began. 
Azathioprine was introduced and prednisone ceased 
by April 2008. In June, she was admitted with massive 
hepatosplenomegaly, weight loss, and fever. CD4+ count 
was 0.14 × 109/L (0.43–1.62 × 109/L), and viral load was 
undetectable (<50 copies/mL HIV-1 RNA). Over the next 
month, all 4 blood cultures grew M. lentiﬂ  avum; after 15 
days, mycobacteria were apparent and M. lentiﬂ  avum was 
conﬁ   rmed 7 days later (day 22). Bone marrow biopsy 
showed granulomata and grew M. lentiﬂ  avum. Urine and 
fecal samples were negative for any mycobacteria. She 
did not produce any sputum. Chest radiograph showed 
extensive miliary nodules, and computed tomography 
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Figure 1. Number of patients from whom Mycobacterium lentiﬂ  avum 
was isolated, by year of isolation, Brisbane, Queensland, Australia, 
2001–2008.
Table 2. Characteristics of patients from whom Mycobacterium lentiflavum was isolated and source of isolate, Queensland, Australia, 
2001–2008* 
Characteristic
No.
patients
Median age, y (range); 
sex, M/F 
Source, no. isolates 
Bronchial
washing  Sputum
Wound
swab/aspirate  Other 
Adults
  Significant clinical illness  3 49 (42–85); 0/3  2 0 0 Blood, 1 
  Nonsignificant clinical illness  18 67 (22–88); 12/6  9 4 4 Blood, 1 
  Probable nonsignificant clinical illness 4 74 (59–81); 3/1  1 2 0 Ascites, 1 
  Nonsignificant clinical illness with MAC  7 66 (49–75); 4/3  0 7 0 0
Children 
  Significant clinical illness  1 1.6; 0/1  0 0 1 0
  Nonsignificant clinical illness 3 12 (1.6–17); 1/2  0 2 1 0
*MAC, Mycobacterium avium complex. RESEARCH
(CT) showed peribronchial thickening and bronchiolitis 
but no lymphadenopathy. The patient was empirically 
given isoniazid, rifampicin, pyrazinamide, clarithromycin, 
and ethambutol. Oral prednisone (25 mg 1×/d) improved 
symptoms and liver biochemistry and decreased splenic 
size. She was discharged on prednisone (15 mg 1×/d), 
isoniazid (300 mg 1×/d), ethambutol (400 mg 2×/d), and 
clarithromycin (500 mg 2×/d). Her organomegaly improved 
over the next 6 months. The intravenous port was removed. 
Ten months later, she remained well and compliant with 
treatment.
Case 2: Chronic Pulmonary Nodules and 
Bronchiectasis
In December 2007, an 85-year-old woman sought care 
for lobar pneumonia. She had never smoked and had no 
previous lung disease or immunosuppression. At follow-up 
after discharge from the hospital, she was lethargic with 
a persistent cough but no weight loss or fever. CT of her 
thorax conﬁ  rmed bilateral well-deﬁ  ned nodules up to 1 cm 
in diameter. Bronchoscopic washings grew mycobacteria, 
but the organism could not be speciated. Results of a 
percutaneous nodule biopsy were nondiagnostic. Surgical 
biopsy of the right lung found caseating granulomata, but 
culture was negative. At 7 months follow-up, a CT scan 
of her thorax showed no change in the nodules, but mild 
bronchiectasis had developed. Bronchoscopic lavage grew 
M. lentiﬂ  avum for the ﬁ  rst time. In February 2009, she 
began ethambutol (800 mg), rifampin (450 mg 1×/d), and 
clarithromycin (500 mg 2×/d). Her symptoms improved, 
and she completed 18 months of treatment. Bronchoscopic 
washings posttreatment were ZN stain and AFB culture 
negative.
Case 3: Bronchiectasis
A 49-year-old Taiwanese woman who had never 
smoked sought care in 1998 for hemoptysis. She had 
moved to Australia 5 years earlier. Thoracic CT showed 
a right middle lobe inﬁ   ltrate. Three sputum samples 
were culture negative for AFB. Transbronchial lung 
biopsy samples showed peribronchial granulomata but 
were culture negative. She received empirical quadruple 
therapy for tuberculosis. The cough continued but without 
hemoptysis. In 2004, a chest radiograph showed middle 
lobe and lingular bronchiectasis. Three sputum samples 
were AFB culture negative. Bronchoscopic washings were 
ZN negative but grew M. lentiﬂ  avum, thought to represent 
colonization. In 2007, an unspeciated NTM grew on 1 of 
3 sputum specimens. By January 2009, the patient was 
well, with no exacerbations in the previous year and stable 
radiographic appearance.
Case 4: Cervical Lymphadenitis
A 20-month-old girl was examined for a 4-week history 
of bilateral cervical lymphadenopathy. The largest node 
(20 × 24 mm) was excised. Necrotizing granulomata were 
seen. M. lentiﬂ  avum was cultured. No antimycobacterial 
therapy was administered; she recovered fully.
Nonsigniﬁ  cant Isolates
A 29-year-old woman underwent bilateral lung 
transplantation. Routine posttransplant bronchial washings 
grew M. lentiﬂ  avum. Despite immunosuppressive therapy, 
no further AFB were cultured from multiple samples in the 
subsequent 2.5 years.
In 7 patients (mean age 62 years, 4 male), 1 or 2 
isolates of M. lentiﬂ  avum grew from sputum in the context 
of MAC disease or colonization. Four of these patients 
were concurrently treated for MAC; 1 had recently 
completed treatment; 2 received no treatment for NTM 
and continue under surveillance. All 7 had underlying lung 
disease (2 cavitatory, 5 bronchiectatic). In no instance was 
M. lentiﬂ  avum speciﬁ  cally treated. In addition, sputum of 3 
patients grew M. interjectum, M. fortuitum, or M .abscessus.
From 3 otherwise healthy patients (40-year-old man, 
psoas abscess; 2-year-old girl, cervical lymphadenitis; 
54-year-old man, neck abscess), M. lentiﬂ  avum and 
Staphylococcus aureus were cultured. All patients 
recovered fully after treatment with ﬂ  ucloxacillin with or 
without drainage. No samples were taken for histologic 
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Figure 2. Urban catchment area and locations of persons and 
potable water fro    m which Mycobacterium lentiﬂ  avum was isolated, 
Brisbane, Queensland, Australia, 2001–2008. Gray shading, 
approximate urban extent; circle, 20-km radius from central 
business district.M. lentiﬂ  avum in Drinking Water Supplies
examination, but cytologic examination of a lymph node 
aspirate from the child showed lymphocytes, macrophages, 
neutrophils, and fragments of epithelioid histiocytes but no 
well-formed granulomas. From 2 other patients (35-year-
old woman, chronic leg ulcer; 59-year-old woman, post 
thyroidectomy wound abscess), M. lentiﬂ  avum without S. 
aureus were cultured; the patients were treated with wound 
debridement and ﬂ  ucloxacillin. Biopsy samples showed no 
granulomata.
Most other isolates were cultured from respiratory 
samples. One isolate each was grown from ascitic ﬂ  uid 
and blood. Three patients with cystic ﬁ  brosis (2 with mild 
disease, 1 lung transplant recipient) had 1 or 2 isolates each 
but no evidence of disease.
Strain Types
DiversiLab patterns were grouped into 7 rep-PCR 
proﬁ  les, A–G (Figure 3). The 8 clinical isolates of proﬁ  le 
A showed 97%–99% similarity. This proﬁ  le  included 
2 clinically signiﬁ   cant isolates (cases 1 and 3) and 6 
nonsigniﬁ  cant isolates (3 respiratory samples, 2 soft tissue 
samples, and 1 ascites sample). Two further pulmonary 
isolates (proﬁ  les A1 and A2) were ≈90% similar to the 
proﬁ   le A isolates. The isolate from case-patient 2 was 
contaminated and could not be analyzed. The isolate 
from case-patient 4 (proﬁ  le B) had 94% similarity to a 
nonsigniﬁ   cant isolate from soft tissue. These 2 isolates 
were from patients who lived 1,800 km apart.
Proﬁ  le D comprised a pair of nonsigniﬁ  cant pulmonary 
isolates of 97% similarity. These isolates came from 
patients who lived within 80 km of each other, 450 km 
north of Brisbane. Proﬁ  les C and E were nonsigniﬁ  cant 
isolates and distinct from other rep-PCR proﬁ  les.
Five water sample isolates (proﬁ  le A3) had 97%–99% 
similarity and shared 90% similarity with the clinical 
isolates of proﬁ  les A, A1, and A2. The other 2 water isolates 
(proﬁ  les F and G) were distinct from all other clinical and 
water isolates.
Global Case Reports
In 30 cases of clinically signiﬁ  cant disease published 
in English (online Appendix Table, www.cdc.gov/EID/
content/17/3/395-appT.htm), disease spectrum varied 
from cervical lymphadenitis (8 of 9 cases in children) to 
acute or chronic disease usually affecting lungs and pleura 
(inﬁ  ltrates, cavities, nodules, effusions) but also arthritis/
discitis, bone lesions, skin ulcers, and hepatosplenomegaly. 
The rapid onset of cervical lymphadenitis has been noted 
in many reports, usually with an excellent outcome 
from excision alone. The mean age of adults with 
nonlymphadenitis disease (20 cases) was 56 years (range 
23–87 years), and they were evenly split between the sexes. 
Eleven case-patients had associated immunocompromise. 
Eleven were reportedly stable or improved at follow-up, 6 
died, and 3 had uncertain outcomes.
Discussion
M. lentiﬂ  avum disease can be difﬁ  cult to diagnose, 
as the cases in this report exemplify. The clinical 
information we gathered was largely retrospective, which 
poses certain limitations; however, the case-patients 1 
and 2 were current patients undergoing active treatment 
at the time of writing (June 2009). M. lentiﬂ  avum 
was isolated occasionally from patients colonized or 
undergoing treatment for MAC and in patients with S. 
aureus soft tissue infections. Certainly in some patients 
multiple NTM can grow at the same or different times, 
and M. lentiﬂ  avum may be no different in this respect. 
M. lentiﬂ  avum has been cultured from sputum containing 
MAC and from sputum containing M. tuberculosis, but 
these cases may represent colonization/contamination 
rather than infection (23,28). Concurrent isolation of M. 
lentiﬂ  avum and S. aureus, which probably represents 
contamination or colonization, has not been reported as 
far as we are aware. Co-infection of S. aureus and M. 
tuberculosis has been reported, possibly as superimposed 
staphylococcal infection in tuberculous tissue (29,30). 
Although no samples were taken for histology, cytologic 
examination of lymph node aspirate from the 2-year-
old child with lymphadenitis is intriguing because the 
inﬂ   ammatory cells were predominantly lymphocytes/
macrophages with epithelioid histiocytes. Treatment 
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Figure 3. Dendrogram and virtual gel images representing rep-
PCR  ﬁ   ngerprint patterns of 16 human and 7 water isolates of 
Mycobacterium lentiﬂ  avum, Brisbane, Queensland, Australia, 
2001–2008. CI, clinical isolate; W, potable water isolate; BAL, 
bronchoalveolar lavage. *Clinically signiﬁ  cant isolate.RESEARCH
using ﬂ  ucloxacillin with or without drainage affected a 
complete cure in all cases.
M. lentiﬂ  avum is a rare isolate and an unusual cause of 
disease in humans. As with other NTM, it can be isolated 
from contaminated samples: clinical signiﬁ  cance should 
be assessed before any treatment is considered (2). In 
2005, of 488 patients with pulmonary NTM isolates in 
Queensland, only 26.6% were considered to have clinically 
signiﬁ  cant disease (31). The proportion was higher for M. 
intracellulare (39.4%), M. avium (33.3%), and M. kansasii 
(52.6%) and much lower for species traditionally thought 
to be more likely contaminants, e.g., M. gordonae (11.1%). 
In our study, isolates for 4 (11%) of 36 were clinically 
signiﬁ   cant, similar to published estimates of 10%–21% 
(16,22). This proportion may be an underestimate given 
that we could not determine clinical signiﬁ   cance in 4 
patients. Worldwide, M. lentiﬂ  avum may be underreported 
and incorrectly identiﬁ  ed as other, more familiar species, 
especially if access to molecular identiﬁ  cation is limited.
M. lentiﬂ  avum has been isolated from water distribution 
samples. Torvinen et al. isolated NTM from up to 80% of 
sites across Finland (32); M. lentiﬂ  avum was the second 
most common species (38% of sites). Laboratory isolation 
of  M. lentiﬂ  avum from clinical specimens in Finland 
has increased independently of speciation methods, 
but details of patients with disease are lacking (33). In 
South Korea, Lee et al. found mycobacteria in 26% of 84 
drinking water sites. Sixty-ﬁ  ve percent of isolates were M. 
lentiﬂ  avum (34). In our study, mycobacteria were isolated 
from 70% of sites, but M. lentiﬂ  avum from only 6.3%. 
The difﬁ   culties in isolating mycobacteria from potable 
water are well recognized and relate to mycobacterial 
growth characteristics and the need for specimen 
decontamination to reduce bacterial and fungal overgrowth. 
Decontamination reduces mycobacterial yields; hence, the 
prevalence of mycobacteria in potable water samples is 
believed to substantially underestimate the true ﬁ  gure (8). 
Culture-based techniques may be less sensitive than direct 
PCR. However, detecting mycobacterial DNA does not 
necessarily prove the presence of viable organisms that 
are able to cause infection; detection of M. lentiﬂ  avum by 
culture-based methods is noteworthy with respect to human 
health. Case-patient 1 had long-term intravenous access, 
which may have allowed direct exposure to contaminated 
water through illicit drug administration. In this report, 
we have geographically associated culture-positive water 
samples and clinical disease.
DiversiLab strain typing showed that proﬁ  les A and 
A3 were most prevalent among clinical and water isolates 
and shared ≈90% similarity. The criteria for interpreting 
rep-PCR typing results have been established for some 
mycobacterial species. For example, Cangelosi et al. found 
high concordance between restriction fragment-length 
polymorphism and rep-PCR, reporting 93% similarity 
as the cutoff value for clustered M. tuberculosis isolates 
and 92% for M. avium (6). The analysis of M. abscessus 
by Zelazny et al., the largest study of rep-PCR in NTM, 
used rep-PCR to successfully cluster M. abscessus strains 
that were clonally related by PFGE analysis (35). Four of 
the water samples constituting proﬁ  le A3 and 1 unrelated 
strain (proﬁ  le G) came from sites that shared a groundwater 
source. These ﬁ  ndings suggest a dominant environmental 
strain closely related (90%), but not identical, to strains 
found in human specimens and as a cause of human disease. 
The theory of dominant local environmental strains is 
supported by the ﬁ  nding of a different strain type from 2 
patients living near each other but 450 km from Brisbane 
(proﬁ  le D).
Proﬁ   le A contained clinically signiﬁ  cant  and 
nonsigniﬁ  cant isolates. Proﬁ  le B also contained a pair of 
highly similar isolates (94%) of which 1 was clinically 
signiﬁ   cant. Although the residential addresses of these 
patients were 1,800 km apart, nothing is known about 
the duration of residence or travel or work habits of these 
case-patients. Thus, the infection may not have been 
acquired locally. Conclusions cannot be drawn about the 
pathogenicity of different strains; a larger study is required 
to address this question.
The  ﬁ   nding of different, less common strain types 
(proﬁ  les E, F, G) conﬁ  rms the validity of using automated 
rep-PCR (DiversiLab) as a tool for strain typing this 
species. Variation in M. lentiﬂ  avum strain type has been 
demonstrated. Buijtels et al. (20) reported 55 M. lentiﬂ  avum 
isolates from 149 specimens obtained from 38 patients at 1 
hospital in Zambia. Illness of 2 patients deﬁ  nitely fulﬁ  lled 
ATS/IDSA criteria for signiﬁ   cant disease. Because this 
species is a rare cause of disease, the authors performed 
molecular identiﬁ   cation on a subset of 12 isolates to 
investigate the possibility of laboratory contamination. Six 
strain types were identiﬁ  ed; the Zambian strains clearly 
differed from comparator Dutch strains. The ﬁ  nding of a 
dominant strain probably represented the local endemic 
strain, but laboratory or point-of-collection contamination 
could not be entirely excluded. Because isolates in our 
study came from multiple laboratories statewide at different 
times, contamination is unlikely to explain their presence in 
multiple clinical specimens.
The optimal treatment for M. lentiﬂ  avum disease is not 
established; a wide variety of regimens has been used in 
previous case series. Although evidence does not support 
the use of any speciﬁ  c regimen, we achieved symptomatic 
and radiologic improvement in case-patients 1 and 2 
with rifampicin/ethambutol/clarithromycin at 12 months 
and isoniazid/ethambutol/clarithromycin at 18 months, 
respectively. More detailed reporting of treatment regimes 
and outcomes will help establish optimum therapy.
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